Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7W0JE)

Drug Name

LEO 124249 Drug Info

Synonyms

delgocitinib; Delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]
Eczema	EA80-EA89	Phase 2	[1]

Cross-matching ID

PubChem CID: 50914062
CAS Number: CAS 1263774-59-9
TTD Drug ID: DM7W0JE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase (PTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[2]
Abrocitinib	DM8J29L	Atopic dermatitis	EA80	Approved	[1]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[3]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[4]
KD019	DMEFW3G	Brain metastases	2D50	Phase 2	[4]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[1]
TD-1473	DMJG7AY	Ulcerative colitis	DD71	Phase 1	[3]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[5]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[5]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase (PTK)	TTJSQEF	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.